AI

Exscientia and EQRx have announced a strategic research and development collaboration agreement aiming to substantially accelerate the delivery of novel medicines.

The collaboration will leverage the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology, further expanding the breadth of EQRx’s pipeline of novel therapies.

Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate its use of data and digital technologies.

The collaboration will focus on three global health enablers: identifying and integrating complex data sources related to health; advancing the application of artificial intelligence, machine learning, and geo-spatial analytics to these data; and expanding access to technology in remote and underserved locations.

Artificial intelligence firm Behold.ai has won a share of £140 million in government funding for its red dot lung cancer detection platform, as part of the Artificial Intelligence in Health and Care Award.

The award will fund the set-up of two clinical trials sites for the red dot platform in NHS radiology departments, allowing the company to collect further data and support future national roll-out.

UK-based AI pioneers Exscientia has announced the purchase of rival AI firm Allcyte for €50 million.

The multimillion deal, paid in cash and stocks, will give Exscientia ownership of a technology platform that takes patient samples and tests them against a library of approved or experimental drugs, using an AI-enabled imaging system to determine which compounds are having an effect.

Image illustrates output by the software

Cambridge-based AI company, Lucida Medical, has received CE marking for its new machine learning-based prostate cancer detection software, Prostate Intelligence (Pi).

Lucida is one of the first companies in the world to commercialise artificial intelligence (AI) software to identify cancer in prostate MRI scans, with the marking enabling the technology to be deployed in the NHS and other European healthcare systems.

Ori Biotech and Vineti have announced a strategic partnership to produce pre-integrated solutions to fast-track and streamline the manufacture and delivery of cell and gene therapies (CGTs).

The two companies will enter into a non-exclusive partnership to help develop systems to aid the production of CGTs, providing infrastructure and technology solutions for therapy developers, contract manufacturers, and academic centres.

Artificial intelligence (AI) pharmatech company, Exscientia, has announced a collaboration with Bristol Myers Squibb to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology.

The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory, and commercial payments that take the potential value of the deal beyond $1.2 billion.

Photo by Martin Lopez from Pexels

In response to emerging variants of COVID-19, Oxford University and Oracle have created a Global Pathogen Analysis System (GPAS), combining Oxford’s Scalable Pathogen Pipeline Platform (SP3) with Oracle Cloud Infrastructure (OCI), working to help identify new variants and those of concern.

The collaboration builds on the work of a Wellcome Trust-funded consortium, including Public Health Wales, the University of Cardiff, and Public Health England.